Nonlinear pharmacokinetics of misonidazole and desmethylmisonidazole in the isolated perfused rat liver
- PMID: 7299690
Nonlinear pharmacokinetics of misonidazole and desmethylmisonidazole in the isolated perfused rat liver
Abstract
Dose-dependent elimination of misonidazole (MISO) and its metabolite desmethylmisonidazole (DESMISO) were investigated in the isolated perfused rat liver and saturation kinetics were observed for both compounds. The simplest model which accurately described the DESMISO clearance from the perfusate consisted of a saturable elimination pathway (Vmax 3 = 32 nmol/min, Km3 = 11 micro M) in parallel with a first-order pathway [CL5 (clearance) = 0.21 ml/min]. A similar model was constructed for MISO (Vmax2 = 110 nmol/min, Km2 = 10 micro M, CL4 = 0.36 ml/min), but required an additional saturable pathway (Vmax1 = 226 nmol/min, Km1 = 1850 micro M) to characterize the generation of DESMISO, as suggested by in vitro microsomal studies. A good correlation was demonstrated between DESMISO perfusate concentrations (generated during the course of MISO perfusion) and simulations based on the MISO model which included the microsomal data. The MISO and DESMISO models demonstrate that the relative contributions of the different pathways for MISO and DESMISO elimination are strongly concentration-dependent and that the MISO leads to DESMISO pathway is a minor route. A qualitative similarity in saturation kinetics was observed in the disappearance curves for both MISO and DESMISO from the liver perfusate. MISO In combination with an excess of DESMISO resulted in a marked decrease in the clearance rate of MISO from the liver perfusate. This observation suggest that MISO and DESMISO are metabolized along similar pathways.
Similar articles
-
Comparison of the fate of misonidazole (RO 07-0582) and its metabolite desmethylmisonidazole (RO 05-9963), two hypoxic cell radiosensitizers: penetration properties in tumor bearing rats.J Pharmacol. 1983 Jan-Mar;14(1):67-77. J Pharmacol. 1983. PMID: 6834852
-
Studies on the O-demethylation of misonidazole by rat liver microsomes.Cancer Treat Rep. 1982 Jun;66(6):1343-7. Cancer Treat Rep. 1982. PMID: 7083238
-
Metabolism and excretion of [3H]misonidazole by hypoxic rat liver.Int J Radiat Oncol Biol Phys. 1984 Aug;10(8):1365-70. doi: 10.1016/0360-3016(84)90350-x. Int J Radiat Oncol Biol Phys. 1984. PMID: 6469758
-
The concentration of desmethylmisonidazole in human tumours and in cerebrospinal fluid.Br J Cancer. 1981 Mar;43(3):344-9. doi: 10.1038/bjc.1981.54. Br J Cancer. 1981. PMID: 7225285 Free PMC article.
-
Corticosteroid metabolism in isolated perfused rat liver and kidney. Experimental studies with emphasis on aldosterone.Acta Physiol Scand Suppl. 1995;627:1-42. Acta Physiol Scand Suppl. 1995. PMID: 8848946 Review.
Cited by
-
Microscopic distribution of misonidazole in mouse tissues.Br J Cancer. 1989 Jan;59(1):12-6. doi: 10.1038/bjc.1989.4. Br J Cancer. 1989. PMID: 2757919 Free PMC article.
-
Distribution and tumor penetration properties of a radiosensitizer 2-[14C] misonidazole (Ro 07-0582), in mice and rats as studied by whole-body autoradiography.Cancer Chemother Pharmacol. 1986;17(2):121-6. doi: 10.1007/BF00306739. Cancer Chemother Pharmacol. 1986. PMID: 3719893
-
Novel imaging approaches to head and neck cancer.Semin Oncol. 2008 Jun;35(3):262-73. doi: 10.1053/j.seminoncol.2008.03.001. Semin Oncol. 2008. PMID: 18544441 Free PMC article. Review.
-
Renal elimination of the hypoxic cell radiosensitizer misonidazole in Wistar rats: influence of some drugs on its excretion.Eur J Drug Metab Pharmacokinet. 1985 Jul-Sep;10(3):181-7. doi: 10.1007/BF03189740. Eur J Drug Metab Pharmacokinet. 1985. PMID: 4085520
-
Implications of pharmacokinetic modeling in risk assessment analysis.Environ Health Perspect. 1987 Dec;76:97-106. doi: 10.1289/ehp.877697. Environ Health Perspect. 1987. PMID: 3447907 Free PMC article.